跳到主要內容

臺灣博碩士論文加值系統

(54.173.214.227) 您好!臺灣時間:2022/01/25 13:40
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:李育誠
研究生(外文):Yu-Cheng Li
論文名稱:Pin1-β-catenin-cyclin-D1在食道鱗狀細胞癌之角色及作為化學治療標的之探討
論文名稱(外文):Pin1-β-catenin-cyclin D1 as a potential chemotherapy target for esophageal squamous cell carcinoma
指導教授:呂佩融
指導教授(外文):Pei-Jung Lu
學位類別:碩士
校院名稱:國立中山大學
系所名稱:生物醫學科學研究所
學門:生命科學學門
學類:生物化學學類
論文種類:學術論文
論文出版年:2006
畢業學年度:94
語文別:英文
論文頁數:91
中文關鍵詞:食道癌
外文關鍵詞:Pin1ESCC
相關次數:
  • 被引用被引用:0
  • 點閱點閱:197
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
Pin1在細胞週期中,扮演重要的調控角色。亦有文獻報導指出,Pin1在乳癌形成的過程中,有過度表現的情形且扮演著重要的角色。然而,Pin1與食道癌的關係,特別是國人常罹患的鱗狀細胞癌中,所扮演的角色並不清楚。本研究的目的主要在探討Pin1與食道鱗狀細胞癌之間的關係以及尋找可預防或治療食道鱗狀細胞癌的新藥。在研究中,藉由西方墨點法以及免疫組織染色法,發現超過65%的食道鱗狀細胞癌病人當中,有Pin1蛋白過度表現的情況,且Pin1與其下游的β-catenin and cyclin-D1蛋白的表現,與食道鱗狀細胞癌形成過程中,扮演重要的角色。再者,藉由RT-PCR所得的結果發現,食道鱗狀細胞癌中Pin1蛋白過度表現的結果,主要是因為Pin1 mRNA 量增加所致。重要的是經由統計分析的結果,我們發現Pin1蛋白的過度表現,與食道鱗狀細胞癌病人存活率間有正相關性(p<0.001)。因此,我們認為Pin1可當作食道鱗狀細胞癌預後的指標。此外,也藉由 Pin1 shRNA技術來證明Pin1 suppression可以負向調控β-catenin and cyclin-D1的表現且可以有效的抑制食道鱗狀細胞癌細胞的生長。由以上結果可推論,Pin1 可以當成食道鱗狀細胞癌化學治療的標的。從實驗室建立的小分子chemical library中,我們利用cell proliferation assay,篩選出兼具有抑制Pin-1-β-catenin and cyclin-D1及能抑制細胞分裂的化合物。在化合物篩選過程中,發現其中一個化合物VGHKS-040不但可以有效的抑制食道鱗狀細胞癌細胞的生長(IC50=4.8±0.6μM),也可以影響食道鱗狀細胞癌細胞中Pin1- β-catenin and cyclin-D1蛋白質的表現量。最後,利用colony formation assay以及在SCID小鼠或裸鼠中所建立的人類腫瘤動物模式證明,不管是在in vitro或 in vivo中,VGHKS-040皆可有效的抑制食道鱗狀細胞癌腫瘤的生長。在我們的研究過程中,成功的篩選出了一個可以抑制Pin1的小分子化合物,並可以應用於發展治療食道鱗狀細胞癌新藥的基礎上。
It has been demonstrated that overexpression of Pin1, a novel cell cycle regulator, in human breast cancer and might play an important role in tumorigenesis. However, the role of Pin1 and whether Pin1 is overexpressed in esophageal squamous cell carcinoma (ESCC) remained unclear. There are two specific aims in this study. The first specific aim is to study the correlation between Pin1 and human ESCC cancer. The second specific aim is to discover drugs that can intervent the Pin1 mediated signaling and provide a novel chemotherapy for human ESCC. In this dissertation, we have demonstrated that Pin1 was overexpressed in more than 65% of clinical esophageal cancer tissues and its level correlated with β-catenin and Cyclin D1 expression by western blotting and immunohistochemistry analyses. The RT-PCR results suggested that Pin1 overexpression maybe due to the up-regulation of Pin1 transcription. By statistic analysis, we have demonstrated that ESCC patients with Pin1 overexpression had significantly poorer survival rate than those non-Pin1 overexpression patients (p< 0.001). Pin1 therefore can be used as a prognosis marker for ESCC. In addition, we have demonstrated that Pin1 suppression by shRNA could downregulate β-catenin and Cyclin D1 expression and inhibit ESCC cell proliferation efficiently. Taken together, these results suggest that Pin1-β-catenin and Cyclin D1 could be used as a potential chemotherapy target for ESCC. In order to discover novel drugs in the chemoprevention or therapy of human ESCC, we screened a chemical library using cell proliferation assay. Among them, compound VGHKS-040 not only effectively inhibited the cell proliferation rate in ESCC cell lines with IC50 value of 4.8±0.6μM but also abated protein levels of Pin1, β-catenin, and cyclin D1. By colony forming assay as well as the Xenograft SCID and nude mice model, we have demonstrated that VGHKS-040 can inhibit the tumor growth in vitro and in vivo. These results suggested that VGHKS-040 provide a new avenue for chemotherapy of esophageal squamous cell carcinoma.
Contents

Abstract
Chinese......................................... I
English. .......... ............................. III
Abbreviations...... .................................V
Introduction........................................ 1
Materials and Methods................................ 15
Results ............................................27
Conclusions and Discussions............................ 41
Figures ........................................... 47
References......................................... 66
Appendix.......................................... 71
Ayala G., Wang D.G., Wulf G., Frolov A., Li R., Sowadski J., Wheeler T.M., Lu K.P., Bao L. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 2003; 63: 6244–6251.
Bao L., Kimzey A., Sauter G., Sowadski J.M., Lu K.P. and Wang D.G. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. American J. pathology 2004; 164: 1727-1737.
Campaner S.,Kaldis P., Izraeli S.and Kirsch I.R Sil Phosphorylation in a Pin1 Binding Domain Affects the Duration of the Spindle Checkpoint. Molecular and cellular biolog 2005; 6660–6672.
Crenshaw DG, Yang J, Means AR, Kornbluth S The mitotic peptidyl-prolyl isomerase, Pin1, interacts with Cdc25 and Plx1. EMBO J 1998; 17: 1315-27.
Eckerdt F., Yuan J., Saxena K., Martin B., Kappel S., Lindenau C., Kramer A., Naumann S., Daum S., Fischer G., Dikic I., Kaufmann M., Strebhardt K. Polo-like Kinase 1-mediated Phosphorylation Stabilizes Pin1 by Inhibiting Its Ubiquitination in Human Cells. THE JOURNAL OF BIOLOGICAL CHEMISTRY 2005; 280, 36575–36583.
Hanger D.P., Betts J.C., Loviny L.F., Blackstock W.P.and Anderton B.H. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer''s disease brain using nanoelectrospray mass spectrometry. Journal of Neurochemistry 1998; 71: 2465-76.
Henderson, B.R. Nuclear-cytoplasmic shuttling of APC regulates b-catenin subcellular localization and turnover. Nat. Cell Biol. 2000; 2: 653–660.
Kuang, J., Ashorn, C.L., Gonzalez-Kuyvenhoven, M., and Penkala, J.E. Cdc25 is one of the MPM-2 antigens involved in the activation of maturation-promoting factor. Mol. Biol. Cell 1994; 5: 135–145.
Lim J, Lu K.P. Pinning down phosphorylated tau and tauopathies. Biochimica Biophysica Acta 2005; 1739: 311 –322.
Liou Y.C., Sun A., Ryo A., Zhou X.Z., Yu Z.X., Huang H. et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 2003; 424: 556- 561
Lu K.P. Pinning down cell signaling, cancer and Alzheimer''s disease. TRENDS IN BIOCHEMICAL SCIENCES 2004; 29: 200-209.
Lu K.P. Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics. CANCER CELL 2003; 175-180.
Lu K.P., Hanes S.D., Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996; 380: 544-547.
Lu K.P., Liouand Y.C., Vincent I. Proline-directed phosphorylation and isomerization in mitotic regulation and in Alzheimer’s Disease. BioEssays 2003; 25:174–181.
Lu P.J., Wulf G., Zhou X.Z., Davies P., Lu K.P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 1999; 399: 784–788.
Lu P.J., Zhou X.Z., Liou Y.C., Noel J.P., Lu K.P. Critical role of WW domain phosphorylation in regulating its phosphoserine-binding activity and the Pin1 function. J. Biol. Chem. 2002; 277: 2381–2384.
Lu P.J., Zhou X.Z., Shen M., Lu K.P. A function of WW domains as phosphoserine-or phosphothreonine-binding modules. Science 1999; 283:1325–1328
Pang R., Yuen J., Yuen M.F., Terence C.L., Lee K.W., Man K. Pin1 overexpression and beta-catenin gene mutationare distinct ongogenic events in human hepatocellular carcinoma. Oncogene 2004; 23: 4182-4186.
Raina A.K., Monteiro M.J., McShea A., Smith M.A. The role of cell cycle mediated events in Alzheimer’s disease. Int J Exp Pathol 1999; 80: 71–76.
Ranganathan R., Lu K.P., Hunter T., Noel J.P. Structural and functional analysis of the mitotic peptidyl-prolyl isomerase Pin1 suggests that substrate recognition is phosphorylation dependent. Cell 1997; 89: 875–886.
Rippmann J.F., Hobbie S., Daiber C., Guilliard B., Bauer M., Birk J., Nar H., Garin-Chesa P, Rettig W.J., Schnapp A. Phosphorylation-dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis. Cell Growth Differ 2000; 11: 409-416.
Ryo A., Liou Y.C., Lu K.P. and Wulf G. Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. Journal of Cell Science 2003; 116: 773-783.
Ryo A., Liou Y.C., Wulf G., Nakamura M., Lee S.W., and Lu K.P. PIN1 Is an E2F Target Gene Essential for Neu/Ras-Induced Transformation of Mammary Epithelial Cells Molecular and cellular biology. 2002, 22: 5281–5295.
Ryo A., Nakamura M., Wulf G., Liou Y.G., and Lu K.P. Pin1 regulates turnover and subcellular localization of b-catenin by inhibiting its interaction with APC NATURE CELL BIOLOGY 2001; 3: 793-801.
Ryo A., Uemura H., Ishiguro H., Saitoh T., Yamaguchi A., Perrem K., Kubota Y., Lu K.P. and Aoki1 I. Stable Suppression of Tumorigenicity by Pin1-Targeted RNA Interference in Prostate Cancer American Association for Cancer Research 2005; 11: 7523-7531.
Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, Rottapel R, Yamaoka S and Lu KP Regulation of NF-kB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell 2003; 12: 1413–1426.
Shen, M., Stukenberg, PT, Kirschner, MW and Lu, KP The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes & Dev. 1998; 12: 706-720. Stukenberg P.T., and Kirschner M.W. Pin1 acts catalytically to promote a conformational change in Cdc25. Mol. Cell 2001; 7: 1071–1083.
Woodbury E.L, Shokat K.M., Morgan D.O. Targets of the cyclin-dependent kinase Cdk1. Nature 2003; 425: 859–864
Whitmarsh A.J. and Davis, R.J. Transcription factor AP-1 regulation by mitogenactivated protein kinase signal transduction pathways. J. Mol. Med. 1996;74: 589–607.
Wulf G., Garg P., Liou Y.C., Iglehart D. and Lu K.P. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. The EMBO Journal 2004; 23: 3397–3407.
Wulf G.M., Ryo A., Wulf G.G., Lee S.W., Niu T., Lu K.P Pin1 is overexpressed in breast cancer and potentiates the transcriptional activity of phosphorylated c-Jun towards the cyclin D1 gene. EMBO J. 2001; 20: 3459–3472.
Wulf G.M., Liou Y.C., Ryo A., Lee S.W. and Lu K.P. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage.
J. Biol. Chem. 2002; 277: 47976–47979.
Wulf1 G., Ryo A., Liou Y.C. and Lu K.P. The prolyl isomerase Pin1 in breast development and cancer. Breast Cancer Research 2003; 5: 76-72.
Xu Y.X., Hirose Y., Zhou X.Z., Lu K.P. and Manley J.L. Pin1 modulates the structure and function of human RNA polymerase II. Genes Dev. 2003; 17: 2765–2776.
Yaffe M.B., Schutkowski M., Shen M.H., Zhou X.Z., Stukenberg P.T., Rahfeld J.U., Xu J., Kuang J., Kirschner M.W., Fischer G., Cantley L.C., Lu K.P. Sequence-specific and phosphorylation-dependent isomerization: A potential mitotic regulatory mechanism. Science 1997; 278: 1957-1960.
Yaffe M.B., Schutkowski M., Shen M., Zhou X.Z., Stukenberg P.T., Rahfeld J.U., Xu J., Kuang J., Kirschner M.W., Fischer G., Cantley L.C., Lu K.P. Sequence-specific and phosphorylation-dependent proline isomerization: A potential mitotic regulatory mechanism. Science 1997; 278: 1957–1960.
Zacchi P., Gostissa M., Uchida, T., Salvagno, C., Avolio, F., Volinia, S., Ronai, Z., Blandino, G., Schneider, C., Del Sal, G. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 2002; 419: 853–85.
Zhou X.Z., Kops O., Werner A., Lu P.J., Shen M., Stoller G., Ku¨ llertz G, Stark M., Fischer G., Lu K.P. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell 2000; 6: 873–883.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關論文